-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bausch Health Companies Inc. (NYSE:BHC) Short Interest Down 14.1% in December
Bausch Health Companies Inc. (NYSE:BHC) Short Interest Down 14.1% in December
Bausch Health Companies Inc. (NYSE:BHC – Get Rating) saw a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 26,620,000 shares, a drop of 14.1% from the December 15th total of 30,980,000 shares. Based on an average daily trading volume, of 5,100,000 shares, the days-to-cover ratio is presently 5.2 days. Approximately 7.5% of the company's stock are short sold.
Institutional Investors Weigh In On Bausch Health Companies
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Paulson & CO. Inc. lifted its stake in shares of Bausch Health Companies by 2.3% during the second quarter. Paulson & CO. Inc. now owns 26,439,035 shares of the company's stock worth $221,030,000 after buying an additional 600,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Bausch Health Companies by 2.0% during the third quarter. Vanguard Group Inc. now owns 10,924,375 shares of the company's stock worth $75,268,000 after buying an additional 219,279 shares during the period. Segantii Capital Management Ltd lifted its stake in shares of Bausch Health Companies by 281.3% during the second quarter. Segantii Capital Management Ltd now owns 5,700,000 shares of the company's stock worth $47,652,000 after buying an additional 4,205,000 shares during the period. Fiera Capital Corp lifted its stake in shares of Bausch Health Companies by 12.9% during the second quarter. Fiera Capital Corp now owns 3,445,746 shares of the company's stock worth $28,807,000 after buying an additional 393,903 shares during the period. Finally, Rubric Capital Management LP acquired a new stake in shares of Bausch Health Companies during the third quarter worth $22,492,000. 66.99% of the stock is currently owned by institutional investors and hedge funds.
Get Bausch Health Companies alerts:Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Bausch Health Companies in a report on Wednesday, October 12th. They set a "hold" rating on the stock. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $10.60.
Bausch Health Companies Stock Up 2.7 %
NYSE BHC traded up $0.22 on Monday, hitting $8.37. The stock had a trading volume of 1,573,323 shares, compared to its average volume of 4,428,930. The business's fifty day moving average price is $7.15 and its 200 day moving average price is $6.96. The company has a debt-to-equity ratio of 48.05, a current ratio of 1.05 and a quick ratio of 0.77. Bausch Health Companies has a 52-week low of $4.00 and a 52-week high of $26.39. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 0.12 and a beta of 0.96.Bausch Health Companies (NYSE:BHC – Get Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $0.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.16). Bausch Health Companies had a return on equity of 942.47% and a net margin of 3.13%. The firm had revenue of $2.05 billion during the quarter, compared to analysts' expectations of $2.09 billion. Equities research analysts anticipate that Bausch Health Companies will post 2.97 earnings per share for the current year.
Bausch Health Companies Company Profile
(Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
Read More
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Tractor Supply Company Shares Could be Headed to New Highs
- Is Canadian Solar Too Hot to Handle?
- UiPath is the Blue-Collar AI Platform to Watch in 2023
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
博世健康公司(紐約證券交易所代碼:BHC-GET評級)在12月份看到空頭股數的銷售額大幅下降。截至12月30日,空頭股數共有2662萬股,與12月15日的3098萬股相比,下降了14.1%。根據日均成交量5,100,000股計算,目前天數與回補比率為5.2天。該公司約7.5%的股票被賣空。
機構投資者看好博世健康公司
幾家機構投資者和對沖基金最近改變了他們在該股的頭寸。Paulson&Co.Inc.在第二季度增持了博世健康公司2.3%的股份。Paulson&Co.Inc.目前持有26,439,035股該公司股票,價值221,030,000美元,在此期間又購買了600,000股。先鋒集團(Vanguard Group Inc.)在第三季度增持了博世健康公司2.0%的股份。先鋒集團現在持有10,924,375股該公司股票,價值75,268,000美元,在此期間又購買了219,279股。Segantii資本管理有限公司在第二季度增持了博世健康公司股票281.3%。Segantii Capital Management Ltd在此期間額外購買了420.5萬股後,現在擁有570萬股該公司股票,價值47,652,000美元。Fiera Capital Corp在第二季度增持了博世健康公司12.9%的股份。Fiera Capital Corp目前持有該公司3,445,746股股票,價值28,807,000美元,在此期間又購買了393,903股。最後,Rubric Capital Management LP在第三季度收購了博世健康公司價值22,492,000美元的新股。66.99%的股票目前由機構投資者和對沖基金持有。
到達博世健康公司警報:分析師評級發生變化
另外,StockNews.com在10月12日星期三的一份報告中開始報道博世健康公司的股票。他們對該股設定了“持有”評級。根據MarketBeat.com的數據,五位分析師對該股的評級為持有,該公司目前的共識評級為持有,共識目標價為10.60美元。
博世健康公司股票上漲2.7%
紐約證交所BHC週一上漲0.22美元,觸及8.37美元。該股成交量為1,573,323股,而其平均成交量為4,428,930股。該業務的50日移動均線價格為7.15美元,200日移動均線價格為6.96美元。該公司的債務權益比為48.05,流動比率為1.05,速動比率為0.77。博世健康公司的股價為4.00美元的52周低點和26.39美元的52周高位。該股市值為30.3億美元,本益比為11.64倍,本益比為0.12倍,貝塔係數為0.96。博世健康公司(紐約證券交易所代碼:BHC-GET評級)最近一次發佈季度收益結果是在11月3日星期四。該公司公佈本季度每股收益(EPS)為0.76美元,低於市場普遍預期的0.92美元(0.16美元)。博世健康公司的股本回報率為942.47%,淨利潤率為3.13%。該公司本季度營收為20.5億美元,高於分析師預期的20.9億美元。股票研究分析師預計,博世健康公司本年度每股收益將達到2.97美元。
博世健康公司簡介
(獲取評級)
博世健康公司與其子公司一起開發、製造和營銷一系列藥物、醫療器械和非處方藥(OTC)產品,主要用於眼睛健康、胃腸病和皮膚病等治療領域。該公司通過五個部門經營:博士倫、沙利克斯、國際處方、正畸皮膚科和多元化產品。
閱讀更多內容
- 免費獲取StockNews.com關於博世健康公司(BHC)的研究報告
- 拖拉機供應公司股價可能創新高
- 阿特斯太陽能是不是太辣了,拿不動?
- UiPath是2023年值得關注的藍領人工智慧平臺
- CVS Health正在成長為一家綜合醫療保健組織
- C3.ai Stock是ChatGPT人工智慧的玩法嗎?
接受博世健康公司每日新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對博世健康公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧